Immuneering Total Revenue from 2010 to 2025

IMRX Stock  USD 1.80  0.15  9.09%   
Immuneering Corp Total Revenue yearly trend continues to be fairly stable with very little volatility. Total Revenue will likely drop to 389.03 in 2025. Total Revenue is the total amount of income generated by the sale of goods or services related to Immuneering Corp's primary operations. View All Fundamentals
 
Total Revenue  
First Reported
2010-12-31
Previous Quarter
409.5
Current Value
389.03
Quarterly Volatility
852.5 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Immuneering Corp financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Immuneering Corp's main balance sheet or income statement drivers, such as Net Interest Income of 4.1 M, Interest Income of 4.1 M or Depreciation And Amortization of 425.1 K, as well as many indicators such as Price To Sales Ratio of 207, Dividend Yield of 0.0 or PTB Ratio of 0.0017. Immuneering financial statements analysis is a perfect complement when working with Immuneering Corp Valuation or Volatility modules.
  
Check out the analysis of Immuneering Corp Correlation against competitors.
For more information on how to buy Immuneering Stock please use our How to Invest in Immuneering Corp guide.

Latest Immuneering Corp's Total Revenue Growth Pattern

Below is the plot of the Total Revenue of Immuneering Corp over the last few years. Total revenue comprises all receipts Immuneering Corp generated from the sale of its products or services. It is the total amount of income generated by the sale of goods or services related to the company's primary operations. Immuneering Corp's Total Revenue historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Immuneering Corp's overall financial position and show how it may be relating to other accounts over time.
Total Revenue10 Years Trend
Slightly volatile
   Total Revenue   
       Timeline  

Immuneering Total Revenue Regression Statistics

Arithmetic Mean1,494,174
Geometric Mean358,692
Coefficient Of Variation57.06
Mean Deviation707,312
Median1,919,709
Standard Deviation852,518
Sample Variance726.8B
Range2.3M
R-Value(0.71)
Mean Square Error388.5B
R-Squared0.50
Significance0
Slope(126,759)
Total Sum of Squares10.9T

Immuneering Total Revenue History

2025 389.03
2024 409.5
2023 455.0
2022317 K
20212.1 M
20202.3 M

About Immuneering Corp Financial Statements

Immuneering Corp investors use historical fundamental indicators, such as Immuneering Corp's Total Revenue, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Immuneering Corp. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Total Revenue 409.50  389.03 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Immuneering Stock Analysis

When running Immuneering Corp's price analysis, check to measure Immuneering Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Immuneering Corp is operating at the current time. Most of Immuneering Corp's value examination focuses on studying past and present price action to predict the probability of Immuneering Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Immuneering Corp's price. Additionally, you may evaluate how the addition of Immuneering Corp to your portfolios can decrease your overall portfolio volatility.